
About Dapsone & Persisters
Dapsone, a Leprosy drug, can help some with treatment-resistant Lyme and Bartonella due to persisters plus treatment resistant Babesia. In 2016, Richard Horowitz, MD, and Phyllis Freeman, PhD, published research on 100 patients. The study showed 59 percent of people had improvements with dapsone of 100 mg or less.
More recently, Dr. Horowitz has continued refining a higher-dose approach, publishing a more detailed double-dose/high-dose protocol in 2023.
However, my experience with dapsone is mixed. While it helps some, it is also a very difficult medicine for many to take.
In this article, I review:
- my experience with this novel medicine,
- a specific antibiotic protocol that includes dapsone as a normal-dose regimen,
- how to decrease side effects and Herxheimer reactions on dapsone,
- the risks of using dapsone,
- the chances for treatment success using a dapsone regimen, and
- a detailed look at, and critique of, Dr. Horowitz’s newer double-dose/high-dose protocol and why I don’t support it.
Dr. Marty Ross, MD, on Dapsone for Persistent Lyme Disease
Persisters in Lyme & Bartonella
Borrelia (Lyme) and Bartonella are difficult to treat. While a majority of people do get better following the standard one to two months of antibiotics recommended by the CDC and the IDSA in acute Lyme, 15-20 percent do not.
Borrelia and Bartonella are difficult to recover from for a number of reasons. One reason is that Lyme and Bartonella, like tuberculosis and leprosy, can develop persister cells. Persisters in Borrelia are composed of the spirochetes, cysts, and biofilm communities that grow very slowly or not at all. In Bartonella, persisters occur in biofilms too and also grow slowly or not at all. These persisters essentially go into hibernation where they ignore the antibiotics a person takes. While faster-growing Bartonella or Borrelia are much easier to treat, persisters evade the immune system and the antibiotics we send to poison them.
This article is specifically about dapsone for treating persisters. Adding dapsone is one way to address persisters, though there are a number of persister and treatment resistant approaches. Read more in Persister Lyme & Bartonella Options.
Why Dapsone?
Dapsone is an antibiotic used to treat slow-growing persister bacteria. Because of this, it is regularly used to treat leprosy and a form of skin inflammation called dermatitis herpetiformis. It can also kill malaria and, therefore, it could help treat those with a Babesia coinfection. Finally, dapsone can lower inflammation in lupus, so it could control inflammation in Lyme.
Warning: Dapsone is a Harsh Drug
Dapsone in Lyme is a hard medicine to take.
- In fact, in my Seattle practice, 30 percent of patients do not tolerate this medicine and have to stop taking it. At the November 2017 International Lyme and Associated Diseases conference in Boston, Richard Horowitz, MD, the pioneer of the dapsone approach, spoke of similar findings in his practice during his conference presentation.
- In Horowitz’s 2019 study of 200 patients on a 100 mg dapsone protocol, he notes 46/200 (23 percent) dropped out due to side effects.
Here is what you should know about the possible harm of being on a dapsone protocol:
- Check G6PD levels before you start. Do not use dapsone if you have low Glucose-6-phosphate dehydrogenase (G6PD). This condition mostly affects men. If a person has a G6PD deficiency and they take dapsone, it could cause hemolysis (the tearing apart of the red blood cells). Before starting this medication, your physician should measure a G6PD blood test.
- Dapsone blocks folate metabolism. Dapsone works by blocking folate metabolism in germs, but it also blocks folate metabolism in red blood cells, leading to severe anemia. To prevent this, consider taking up to 65 mg of folate and folinic acid a day (15 mg as 5-MTHF and 50 mg as prescription Leucovorin) while you are on this medication at a 100 mg dose.
- Dapsone suppresses the bone marrow. Red blood cells are manufactured in the bone marrow. Dapsone makes it harder for the bone marrow to make red blood cells. Although this is a separate method from folate metabolism interference, it also can lead to anemia. If anemia is a problem, lowering the dapsone dose can help.
- Dapsone causes severe Herxheimer reactions. I have seen some severe Herxheimer reactions using dapsone. As a result, I start all of my dapsone treatments at low doses and raise them slowly.
- Dapsone can cause an allergic rash. About five percent of people who are allergic to sulfa antibiotics like Bactrim may develop a rash on dapsone. This usually can be managed using anti-histamine approaches. Most patients with sulfa allergies can take dapsone.
- Dapsone can cause methemoglobinemia. In methemoglobinemia, the oxygen carrying protein in red blood cells does not release oxygen into the tissues. This can cause some people to look blue. If this happens, taking up to 2000 mg of liposomal glutathione a day can help. As well, taking prescription methylene blue 50 mg two times a day reverses the situation.
- Dapsone has many side effects. The list of dapsone side effects reads like a list of Herxheimer reactions: it can cause fever, muscle pain, headache, fatigue, dizziness, nausea, and joint pains. In addition, it can cause neuropathy, severe allergic reactions, and other issues.
Because of these problems, dapsone in Lyme is not suitable for everyone.
When to Use Dapsone in Tick-borne Diseases
So, when is the right time to use dapsone in Lyme and tick-borne diseases?
- Try a dapsone regimen for any person who has tried various oral herbal and prescription antibiotic regimens for Lyme over the course of a year or more and does not have good improvements. Before doing so, I try various approaches to move therapy forward that I outline in Can’t Get Better? Do This.
- Use dapsone as an alternative to a trial of IV antibiotics.
- Finally, consider dapsone for a person who has tried IV antibiotics, but who did not have good improvements.
As mentioned above, a person must have a normal G6PD level to try dapsone. Before proceeding with dapsone, review the other persister regimens, which you can read more about in Persister Lyme & Bartonella Options.
The Normal-Dose Dapsone Lyme Persister Regimen
This normal-dose dapsone regimen is based on the research that Horowitz published in 2016.
- Dapsone 25 mg: Start 1 pill every other day for 1 week, then increase to 1 pill daily for a week, then to 2 pills every other day, alternating with 1 pill every other day for a week, then to 2 pills every day. 50 mg is the minimum effective dose. If a person can tolerate this for a week, then continue increasing slowly up to 100 mg a day.
- Cefuroxime 500 mg: 1 pill 2 times a day. Use this to treat the cell wall of the persister spirochetes and for growing forms of the spirochetes. (This antibiotic is optional, while the others in this regimen are essential.)
- Rifampin 300 mg: 2 pills 1 time a day. Use this to treat intracellular Lyme and to treat cyst forms of the germ. If rifampin is not tolerated, a second choice for cyst Lyme is grapefruit seed extract 250 mg: 1 pill 2 times a day.
- Minocycline 100 mg: 1 pill 2 times a day, or Doxycycline 100 mg: 1 pill 2 times a day, or Biaxin 500 mg: 1 pill 2 times a day, or Zithromax 500 mg: 1 pill 1 time a day. These antibiotics block protein production to treat intracellular Lyme. In this regimen, these drugs are interchangeable.
- Liposomal Curcumin 500 mg: 1 pill 3 times a day. Use this as a nutritional support because it may limit Herxheimer die-off reactions. If a Herxheimer reaction is bad, then increase to 2 pills 3 times a day. Liposomal curcumin, which is microscopically wrapped in fat to increase absorption, is better than regular curcumin.
- Liposomal Glutathione 400-500 mg: 2 times a day. As a nutritional support, this also may limit Herxheimer reactions and help with detoxification. Read more in Glutathione: The Great Fixer. For methemoglobinemia, increase the daily dose up to 2000 mg, divided into two daily doses.
- Folate & Folinic Acid: Combine two forms of folate to reach 65 mg if needed. Use 5 MTHF 5 mg 3 pills 1 time a day. This is a methylated folate that may overcome the blockage of folate metabolism caused by dapsone. If you develop anemia at this dose, then add prescription Leucovorin (folinic acid) 25mg 1 or 2 pills a day.
Additional Notes for Normal-Dose Dapsone Regimen
It is critical when doing the dapsone regimen to also take the curcumin, glutathione, and 5 MTHF. The curcumin and glutathione may dramatically improve the problems with Herxheimer reactions and the 5 MTHF (folate) decreases the chances of anemia.
For a sensitive person who may have increased side effects and Herxheimer reactions in this regimen, do not use the cefuroxime until the second or third month of the regimen. At times, it is not necessary to use the cefuroxime at all based on the improvements. It is necessary in the beginning months on this regimen to test blood for anemia, kidney, and liver function monthly.
Try the normal-dose dapsone regimen for a minimum of six months before deciding if it helps a person or not. If it is helping, keep using it as long as a person is improving.
What Doing a Horowitz Double-Dose/High-Dose Protocol Involves
Since the 2016 study above, Dr. Horowitz has continued refining a higher-dose version of dapsone therapy. In 2023, he and colleagues published a much more structured, two-phase protocol: eight weeks of double-dose dapsone combination therapy (DDDCT), followed by a pulse of high-dose dapsone combination therapy (HDDCT). This version layers in azithromycin, pyrazinamide, and much higher doses of methylene blue on top of an already long list of medicines and supplements.
For a detailed, step-by-step approach to implementing the protocol (weekly doses, timing, and sequencing) see Table 1, Table 2, and Table 3 in Horowitz’s 2023 original article.
Below is a category-by-category count of everything the protocol involves, along with a cost estimate for the supplements and over-the-counter items.
Supplements: 25 products (27 with optional add-ons)
(Note: I am reporting some exact product names and purposes provided by Horowitz in his published article. My reporting is not intended to make a disease claim for any products identified; I am merely reporting the reason Horowitz included these items in his protocol.)
- 4 biofilm agents: cinnamon/clove/oregano oil blend, Biocidin*, stevia, peppermint oil
- 4 probiotics: two probiotic blends, Saccharomyces boulardii, a high-count multi-strain probiotic
- 8 detoxification/anti-inflammatory nutrients: NAC, glutathione, alpha lipoic acid, curcumin, sulforaphane glucosinolate, vitamin C, vitamin E, NADH
- 3 folate/B12/iron products: L-methyl folate, methyl B12, iron
- 6 mitochondrial-support products (used for one month after antibiotics stop): ATP 360*, Carnitex*, CoQ Power*, Cardio Ribose*, Mitoprime*, Mito NR*
- Optional add-ons for severe/resistant cases (2): silver hydrosol (Argentyn 23*), EDTA suppositories
Over-the-counter medications: 1
- Alka-Seltzer Gold or sodium bicarbonate (Herxheimer rescue)
Prescription antimicrobials in the core program: 8
- Dapsone
- Hydroxychloroquine (Plaquenil)
- A tetracycline (doxycycline or minocycline)
- Rifamycin (rifampin or rifabutin)
- Macrolide (azithromycin or clarithromycin)
- Pyrazinamide
- Nystatin
- Methylene blue
Additional antimicrobials rotated in as needed for Babesia or Bartonella: 9
Babesia
- Atovaquone
- Clindamycin
- Atovaquone/proguanil (Malarone)
- Tafenoquine
- Ivermectin
- Artemether/lumefantrine (Coartem)
- Low-dose mefloquine
- Disulfiram
Bartonella
- Nitrofurantoin
Additional prescriptions (non-antimicrobial): 4
- Leucovorin (folinic acid, to offset dapsone’s effect on folate metabolism)
- Ondansetron/Zofran (for nausea)
- Cimetidine (to help control elevated methemoglobin)
- Phenazopyridine (for urinary discomfort caused by methylene blue)
Total across all five categories
47 distinct products and medications (49 counting the two optional supplement add-ons)
Why I Don’t Support the Horowitz Double-Dose/High-Dose Protocol
I want to say this clearly: I do not recommend this protocol, and I do not offer it in my practice.
It should be called “The High-Dose Methylene Blue Protocol”
At doses up to 600 mg a day, methylene blue is doing far more than preventing methemoglobinemia: it’s an antibiotic. Methylene blue has anti-persister activity against Borrelia and, combined with rifampin or azithromycin, was able to fully eradicate Bartonella biofilms in the Johns Hopkins lab studies Horowitz himself cites.
Two “supportive” lead-in supplements, Biocidin* and the cinnamon/clove/oregano oil blend, also have antimicrobial effects in the laboratory with documented anti-Borrelia activity. So every patient is taking at least three independent antimicrobial agents on top of 7 conventional antimicrobials and dapsone itself, and no study separates what each contributes.
Learn more about methylene blue: Mighty Methylene Blue for Tick-borne Infections and More.
The side effects mimic the symptoms the protocol is supposed to fix
Dapsone combined with high-dose methylene blue can cause fever, headache, fatigue, dizziness, nausea, joint pain, and bone marrow suppression not fixed with folinic acid or folate, and methemoglobinemia – all of which overlap with a garden-variety Herxheimer reaction. That overlap is dangerous: patients and physicians may push through what’s actually drug toxicity, assuming it’s “healing.” Horowitz’s papers wrongly treat these effects as expected and manageable rather than as a signal to stop.
The study excludes the people who couldn’t finish
Horowitz’s 2023 paper describes its 25 patients as “a convenience sample… out of a patient population of 50 patients offered HDDCT.” Half the people offered this protocol aren’t in the results, and we don’t know how many dropped out from side effects. Reporting only on those who complete a grueling, multi-antibiotic regimen will always look better than the protocol performs in practice.
Horowitz has a history of overstating dapsone benefits
In Horowitz’s first study of standard 100 mg dosing, he publicly noted a 30% drop out rate while failing to mention this in the published paper. Horowitz’s published data showed only 10 to 15 percent average improvement among those who stayed on Dapsone – a very different picture than the oft-cited “59 percent improved.” In the 2023 study, he notes 25 percent of people improve without providing any degree of improvement, except for the 30.5% who he claimed reached full remission.
The researcher is also the evaluator
Horowitz is the treating physician, the study’s sole conceptual author, and one of three people (all from his own practice) who performed the “validation” and “analysis.” There was no control group, no blinding, no independent review, and no IRB oversight (deemed “not required” for a retrospective chart review). That’s a real conflict of interest, not a substitute for the independent trial Horowitz himself has called for. Publicly, he seems more of an advocate cheerleader for his approach rather than an objective reviewer.
Prescriber beware of your medical board
At its peak, this protocol layers eight antimicrobials, over two dozen supplements, and real risks of serotonin syndrome, QT prolongation, hemolysis, and hypertensive crisis. If a patient of mine ended up in the ER with methemoglobinemia or hypertensive crisis on a regimen like this, I would anticipate I would be reported to my medical board. I don’t believe a retrospective, self-analyzed case series of 25 hand-picked patients would hold up as a defense to my medical board. A protocol I can’t defend, I won’t offer.
What the 2023 study actually reported
To be fair: all 25 patients reported improvement, 7 (30.5 percent) reached full remission for 3+ months, and 3 more were symptom-free for 6+ weeks. Bartonella patients did better with the longer pulse; no one with active Babesia reached full remission. Hemoglobin dropped about 3.5 g/dL, recovering with folate. Those numbers are real, but given the survivorship bias, lack of controls, small size, inseparable drug effects, and conflict of interest, I don’t think they tell us what this protocol would do for the average patient.
Does Dapsone for Lyme Persisters Work?
I have seen some wonderful improvements on the normal-dose dapsone regimen. My best situation is a nurse who did years of IV antibiotics with minimal improvements before transferring her care to my Seattle practice. On a 10-point scale, she had energy of six to seven. After using dapsone for a few months, she returned to work as a nurse, experienced improved energy levels to nine out of 10, and reported normal thinking. On average, however, people have improvements of 10-20 percent. As I noted earlier, about 30 percent of patients cannot tolerate the dapsone at all due to side effects. Like Horowitz, I saw improvements in about 59 percent of my patients.
Bottom Line: My Recommendation
Based on everything above, here’s where I land.
I think a trial of the normal-dose dapsone 100mg protocol (started slowly, monitored with regular bloodwork, and given a fair six-month trial) is a reasonable option for the right patient who has failed other chronic Lyme and tick-borne diseases approaches and has a normal G6PD level.
I do not support the double-dose or high-dose Horowitz protocol described above. The evidence for it comes from small, retrospective, unblinded case series run and analyzed by the same physician who developed it, with no control group, and a study sample that excludes half the patients who were offered treatment. Meanwhile, the protocol itself carries real danger: severe side effects that mimic the very Herxheimer reactions it’s meant to produce, a stack of antimicrobials layered on top of each other so that no one can say what’s actually helping, and medication combinations that could land a patient in the emergency room. Without clear evidence of benefit to weigh against that risk, I don’t think the double-dose or high-dose approach is justified for my patients.
Disclaimer*
Use as recommended by your physician or health care provider. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
The ideas and recommendations on this website and in this article are for informational purposes only. For more information about this, see the sitewide Terms & Conditions.
References

About The Author
Dr. Marty Ross, MD is a passionate Lyme disease educator and clinical expert. He helps Lyme sufferers and their physicians see what really works based on his review of the science and extensive real-world experience. Dr. Ross is licensed to practice medicine in Washington State (License: MD00033296) where he has treated thousands of Lyme disease patients in his Seattle practice.
Dr. Marty Ross, MD is a graduate of Indiana University School of Medicine and Georgetown University Family Medicine Residency. He is a member of the International Lyme and Associated Disease Society (ILADS), The Institute for Functional Medicine, and The American Academy of Anti-Aging Medicine (A4M).